Research analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a report issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.
Several other research firms have also issued reports on CLLS. Oppenheimer reiterated an “outperform” rating and set a $11.00 target price on shares of Cellectis in a report on Tuesday, August 8th. JMP Securities reiterated a “market outperform” rating and set a $6.00 target price on shares of Cellectis in a report on Wednesday, November 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.75.
Cellectis Price Performance
Hedge Funds Weigh In On Cellectis
Hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP purchased a new position in Cellectis in the 3rd quarter worth approximately $30,000. Virtu Financial LLC purchased a new position in Cellectis in the 2nd quarter worth approximately $46,000. Balyasny Asset Management LLC purchased a new position in Cellectis in the 3rd quarter worth approximately $42,000. Envestnet Asset Management Inc. raised its holdings in Cellectis by 19.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 20,501 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,305 shares during the last quarter. Finally, OLD Mission Capital LLC raised its holdings in Cellectis by 90.0% in the 1st quarter. OLD Mission Capital LLC now owns 22,329 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 10,577 shares during the last quarter. 25.20% of the stock is currently owned by hedge funds and other institutional investors.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
- Five stocks we like better than Cellectis
- Following Congress Stock Trades
- MarketBeat Week in Review – 11/6 – 11/10
- What Is WallStreetBets and What Stocks Are They Targeting?
- Data giants MongoDB and Snowflake just got upgraded
- How to Invest in Esports
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.